Novogen (NASDAQ:KZIA) Upgraded to “Buy” at Wall Street Zen

Novogen (NASDAQ:KZIA) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other research analysts have also recently weighed in on KZIA. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Novogen in a report on Wednesday, January 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Novogen presently has a consensus rating of “Hold” and an average target price of $19.00.

Novogen Stock Down 4.5%

Novogen stock opened at $8.45 on Friday. The business’s 50-day moving average price is $6.63 and its 200 day moving average price is $7.73. Novogen has a 52 week low of $2.86 and a 52 week high of $17.40.

Novogen (NASDAQ:KZIA) last released its quarterly earnings data on Friday, November 7th. The company reported ($6.14) EPS for the quarter. The business had revenue of $0.59 million during the quarter.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.